Virginia Retirement Systems ET AL purchased a new position in shares of Sangamo Therapeutics Inc (NASDAQ:SGMO) in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 40,000 shares of the biopharmaceutical company’s stock, valued at approximately $678,000.

Several other hedge funds have also modified their holdings of SGMO. Riverhead Capital Management LLC increased its holdings in Sangamo Therapeutics by 218.0% during the 2nd quarter. Riverhead Capital Management LLC now owns 8,267 shares of the biopharmaceutical company’s stock worth $117,000 after purchasing an additional 5,667 shares during the period. Mount Yale Investment Advisors LLC increased its holdings in Sangamo Therapeutics by 2,202.8% during the 2nd quarter. Mount Yale Investment Advisors LLC now owns 8,359 shares of the biopharmaceutical company’s stock worth $119,000 after purchasing an additional 7,996 shares during the period. NumerixS Investment Technologies Inc purchased a new position in Sangamo Therapeutics during the 2nd quarter worth $125,000. Tyers Asset Management LLC increased its holdings in Sangamo Therapeutics by 301.3% during the 2nd quarter. Tyers Asset Management LLC now owns 9,632 shares of the biopharmaceutical company’s stock worth $137,000 after purchasing an additional 7,232 shares during the period. Finally, Quantitative Systematic Strategies LLC purchased a new position in Sangamo Therapeutics during the 2nd quarter worth $155,000. 65.90% of the stock is owned by hedge funds and other institutional investors.

In other news, VP Edward R. Conner sold 5,000 shares of Sangamo Therapeutics stock in a transaction on Thursday, September 6th. The stock was sold at an average price of $14.17, for a total value of $70,850.00. The sale was disclosed in a filing with the SEC, which is available through this link. Also, Director H Stewart Parker purchased 2,000 shares of the business’s stock in a transaction dated Friday, September 7th. The stock was bought at an average price of $13.52 per share, for a total transaction of $27,040.00. The disclosure for this purchase can be found here. Insiders sold a total of 30,000 shares of company stock worth $405,400 over the last quarter. Company insiders own 1.20% of the company’s stock.

Several research analysts have commented on the company. ValuEngine upgraded Sangamo Therapeutics from a “hold” rating to a “buy” rating in a report on Friday. JPMorgan Chase & Co. downgraded Sangamo Therapeutics from an “overweight” rating to a “neutral” rating and reduced their price objective for the stock from $35.00 to $11.00 in a report on Wednesday, November 14th. BidaskClub downgraded Sangamo Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, November 13th. Guggenheim downgraded Sangamo Therapeutics from a “buy” rating to a “neutral” rating and set a $18.00 price objective on the stock. in a report on Friday, November 9th. Finally, Zacks Investment Research downgraded Sangamo Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, October 10th. One research analyst has rated the stock with a sell rating, four have given a hold rating and six have issued a buy rating to the company. The company presently has an average rating of “Hold” and a consensus target price of $19.57.

Shares of NASDAQ:SGMO opened at $11.21 on Monday. Sangamo Therapeutics Inc has a 12-month low of $9.00 and a 12-month high of $27.50. The firm has a market capitalization of $1.14 billion, a PE ratio of -16.01 and a beta of 3.21. The company has a current ratio of 6.32, a quick ratio of 6.32 and a debt-to-equity ratio of 0.07.

Sangamo Therapeutics (NASDAQ:SGMO) last announced its quarterly earnings results on Thursday, November 8th. The biopharmaceutical company reported ($0.13) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.15) by $0.02. Sangamo Therapeutics had a negative return on equity of 22.06% and a negative net margin of 88.78%. The business had revenue of $23.56 million for the quarter, compared to the consensus estimate of $26.96 million. During the same period last year, the business posted ($0.15) EPS. The business’s revenue was up 99.5% compared to the same quarter last year. On average, equities research analysts forecast that Sangamo Therapeutics Inc will post -0.71 EPS for the current year.

COPYRIGHT VIOLATION NOTICE: This piece was originally published by Daily Political and is owned by of Daily Political. If you are viewing this piece on another website, it was stolen and republished in violation of United States and international trademark and copyright law. The legal version of this piece can be accessed at https://www.dailypolitical.com/2018/11/19/virginia-retirement-systems-et-al-purchases-new-position-in-sangamo-therapeutics-inc-sgmo.html.

About Sangamo Therapeutics

Sangamo Therapeutics, Inc focuses on translating science into genomic therapies that transform patients' lives using platform technologies in genome editing, gene therapy, gene regulation, and cell therapy. The company's zinc finger DNA-binding protein (ZFP) technology enables specific genome editing and gene regulation.

Further Reading: Cash Flow Analysis in Stock Selection

Want to see what other hedge funds are holding SGMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sangamo Therapeutics Inc (NASDAQ:SGMO).

Institutional Ownership by Quarter for Sangamo Therapeutics (NASDAQ:SGMO)

Receive News & Ratings for Sangamo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.